Safety and efficacy of dendritic cell vaccine for COVID-19 prevention after 1-Year follow-up: phase I and II clinical trial final result

IntroductionInterim analysis of phase I and phase II clinical trials of personalized vaccines made from autologous monocyte-derived dendritic cells (DCs) incubated with S-protein of SARS-CoV-2 show that this vaccine is safe and well tolerated. Our previous report also indicates that this vaccine can...

Full description

Bibliographic Details

Published in:	Frontiers in Immunology
Main Authors:	Jonny Jonny, Terawan Agus Putranto, Martina Lily Yana, Enda Cindylosa Sitepu, Raoulian Irfon, Bunga Pinandhita Ramadhani, Muchlis Achsan Udji Sofro, Yetty Movieta Nency, Endang Sri Lestari, Ria Triwardhani, Mujahidah, Retty Karisma Sari, Nur Alaydrus Soetojo
Format:	Article
Language:	English
Published:	Frontiers Media S.A. 2023-06-01
Subjects:	COVID-19 vaccine dendritic cells SARS-CoV-2 clinical trial autologous vaccines
Online Access:	https://www.frontiersin.org/articles/10.3389/fimmu.2023.1122389/full